Skip to main content
ACH logo

Accendra Health, Inc. (ACH) Stock: Price, Forecast & Analyst Target

Accendra Health, Inc. (ACH) — MoonshotScore 30/100 (Weak band), calculated Nov 18, 2026. Price $0.0857 (-35.08%), as of the Nov 18, 2026 trading session; market cap $6.60M. Expected results Oct 29, 2026.

Educational signal · not a buy or sell recommendation · How to read this

Market value / cash and investments (classification unverified): 0.86× (cash as of Jun 30, 2026) · expected results Oct 29, 2026

$0.0857 −$0.0463 (-35.08%) Market Cap $6.60M

Accendra Health, Inc. · ACH · NYSE · Healthcare · Medical - Distribution

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct.

Price as of Nov 18, 2026

Key Statistics

30 of 100

MoonshotScore v2 · Accendra Health (ACH)

Weak
Business Quality Elite (82)
Financial Safety Fragile (15)
Valuation Bubble (14)
Growth Durability Fading (38)
Momentum Falling (11)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality, but a fragile balance sheet, weak growth and an expensive valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone and losses on top of negative retained earnings. Business Quality: Elite; Financial Safety: Fragile; Valuation: Bubble; Growth Durability: Fading; Momentum: Falling.

Earnings yield is the main valuation drag relative to sector peers.

  • quarterly revenue $697M (Q3 FY2025, quarter ended Sep 2025)
  • EPS beat 0 of the last 4 reports
  • Altman Z 0.17 · Piotroski F 3

Holding back: balance-sheet strain, a rich price, weak price trend

Helping: business quality

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for ACH (57 recorded, newest six shown)
RecordedScoreBand
28Weak
28Weak
28Weak
28Weak
30Weak
30Weak

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$0.0857
Change on the day-35.08%
52-week range$0.0857–$5.69
Market capitalisation$6.60M—
Shares traded on the day3.20M
Beta (volatility vs the S&P 500)1.53

Price & events

Events behind the price

  • · Earnings results · below the recorded estimate
  • · Earnings results · above the recorded estimate
  • · Earnings call · management outlook
  • · Earnings results · below the recorded estimate

Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.

Management outlook

As of

  • As a result, and as shown on Slide 11, we have revised the 2026 full-year outlook for revenue to be between $2.45 billion and $2.55 billion, and a full-year adjusted EBITDA to be between $300 million and $320 million.

    Jonathan Leon · Statement from

  • We expect the arrangements to go live later this year and believe they will both lower our operating cost and reduce inventory, thereby improving cash flow.

    Edward Pesicka · Statement from

How to read these dates

A statement's date is the earnings call where it was made, not a deadline. Management expectations can change.

Read management statements

Other perspectives

Council score for Accendra Health (ACH): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Strong
Financial Safety Negative
Valuation Negative
Growth Durability Weak
Momentum Negative

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Neutral read

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Undervalued
Profit Margin Weak
Gross Margin Moderate

Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Accendra Health (ACH), and what does it report?

Short answer

Accendra Health, Inc., along with its subsidiaries, operates globally as a comprehensive provider of healthcare solutions. The organization is structured into two primary operational divisions: Products & Healthcare Services and Patient Direct. Accendra Health, Inc. (ACH) is listed on NYSE. Healthcare / Medical Distribution Headquarters: 4435 Waterfront Drive, Suite 300, Glen Allen, VA. It employs 6,500 people and is led by Edward A. Pesicka. In Q3 FY2025 it reported revenue of $697M and net income of -$150M. The market values it at $6.60M.

2 · Latest results

What do the latest results show for Accendra Health (ACH)?

Short answer · as of

The most recent reported quarter, Q3 FY2025, carried revenue of $697M. Against analyst estimates the company has EPS beat 0 of the last 4 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Latest quarter · revenue
$613.23M Jun 30, 2026
Latest quarter · SG&A
$243.56M Jun 30, 2026
Latest quarter · FMP standardized operating result
−$35.15M Jun 30, 2026
Period endRevenueR&DSG&AFMP standardized operating result
Jun 30, 2026$613.23MNot available$243.56M−$35.15M
Mar 31, 2026$627.78MNot available$255.23M$22.80M
Dec 31, 2025$708.97MNot available$271.50M$51.76M
Sep 30, 2025$697.26MNot available$265.84M$56.36M
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Did results meet expectations?

Reported earnings and revenue alongside the estimates recorded by the provider.

Latest report · revenue
$613.20M Aug 10, 2026
Latest report · revenue estimate
$628.66M Aug 10, 2026
Latest report · revenue vs estimate
Below estimate Aug 10, 2026
Latest report · EPS vs estimate
Below estimate Aug 10, 2026
Report dateRevenue · reportedRevenue · estimateEPS · reportedEPS · estimate
Aug 10, 2026$613.20M$628.66M−$0.1900−$0.0838
May 11, 2026$627.80M$644.18M−$0.0400−$0.0600
Feb 19, 2026$708.97M$713.43M$0.2100$0.2200
Oct 30, 2025$697.26M$714.79M$0.2500$0.2300
How to read these figures

Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q3 FY2025$697M-$150M-$1.94 (diluted)
Q4 FY2025$709M-$56M-$0.73 (diluted)
Q1 FY2026$628M-$6M-$0.08 (diluted)
Q2 FY2026$613M-$89M-$1.16 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Accendra Health (ACH)?

Short answer

Cash and investments (classification unverified) were $7.70M at the Jun 30, 2026 balance-sheet date. Operating cash flow was −$26.01M for the quarter ended Jun 30, 2026, meaning operations used cash. These figures do not establish a cash runway. The MoonshotScore pillars rate business quality as strengths. What is holding it back is balance-sheet strain, a rich price, weak price trend. The distress and quality screens read Altman Z 0.17 · Piotroski F 3. Trailing ratios: ROA 0.2% · current ratio 0.41.

Data-derived red flags

  • Listing risk — at $0.0857 the shares sit below the $1.00 minimum bid NYSE requires for continued listing.
  • Financial-distress signal — its Altman Z-Score of 0.17 sits in the distress zone (elevated bankruptcy risk).
  • Inconsistent delivery — missed Wall Street EPS estimates in 2 of the last 4 reported quarters.

How much cash does the business generate or use?

Quarterly operating cash flow shows cash generated or used by operations.

Latest quarter · operating cash flow
−$26.01M Jun 30, 2026
Previous quarter · operating cash flow
−$50.08M Mar 31, 2026
Period endOperating cash flowCapital expenditure (reported)
Jun 30, 2026−$26.01M−$47.59M
Mar 31, 2026−$50.08M$72.00M
Dec 31, 2025$68.19M−$9.28M
Sep 30, 2025−$172.52M−$57.83M
How to read these figures

Amounts are in US dollars. Negative operating cash flow means the business used cash. Capital spending is shown as reported; we do not combine it into a free-cash-flow or runway estimate. The bars share one scale.

4 · What to check next?

What should you watch next at Accendra Health (ACH)?

Short answer · as of

Current published price targets run low $1.50 · high $1.50 · consensus $1.50 · median $1.50 against a quoted price of $0.0857 (as of Nov 18, 2026).

What management is planning

Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.

  1. Efforts are constructively trending toward resolution in the third quarter, and we believe realized cash flow will improve upon conclusion.

    Jonathan Leon ·

2 more statements are quoted under Upcoming events

What the records here don't tell us

  • The newest quarter held here (Q3 FY2025) was filed Oct 31, 2025 — 12 months ago.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Accendra Health compare with its peers?

Short answer

Accendra Health's score ranks 7th of 7 in the bounded comparison shown, against 6 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Guardian Pharmacy Services, Inc. (GRDN) Same industry, near in market value$48.83 Nov 18, 2026$3.09B96 5-pillar Nov 18, 2026
McKesson Corporation (MCK) Named competitor$1084.43 Nov 18, 2026$125B92 5-pillar Nov 18, 2026
Cardinal Health, Inc. (CAH) Named competitor$278.35 Nov 18, 2026$64.3B88 5-pillar Nov 18, 2026
Cencora, Inc. (COR) Same industry, near in market value$348.28 Nov 18, 2026$66.5B86 5-pillar Nov 18, 2026
Henry Schein, Inc. (HSIC) Same industry, near in market value$85.69 Nov 18, 2026$9.47B73 5-pillar Nov 18, 2026
Prestige Consumer Healthcare Inc. (PBH) Same industry, near in market value$50.62 Nov 18, 2026$2.40B63 5-pillar Nov 18, 2026
Accendra Health (ACH) — this page$0.0857$6.60M30

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$1.50 – $1.50
Consensus target
$1.50
Median target
$1.50

Consensus record · Captured .

Measured against a quoted price of $0.0857 (as of Nov 18, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Oct 5, 2026

Transactions
2
Identified insiders
2
Purchases
0
Sales
0
Other transactions
2

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Reporting holders
1 Period end Jun 30, 2026
Previous quarter · holders
1 Prior to period end Jun 30, 2026
Holders in provider snapshotShares
Huntington National Bank1

Tracked investors

Which of the 16 named investors we follow held ACH in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ACH in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Holder snapshot as of Jun 30, 2026. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Accendra Health (ACH)?

Read these with our analysis →

Common Questions About ACH (Healthcare)

These answers are editorial: 1 of these 9 answers is drawn from the ACH research dossier (written May 5, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.

What does the MoonshotScore mean for ACH?

ACH carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. Accendra Health, Inc. is a healthcare solutions company providing products and services to healthcare providers and patients.

Is ACH a good stock to buy?

Stock Expert AI does not rate ACH buy, sell or hold. Accendra Health, Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ACH stock price today?

The last price recorded for Accendra Health, Inc. (ACH), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the ACH price target?

The analyst consensus price target for Accendra Health, Inc. (ACH), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

What does Accendra Health, Inc. do?

Accendra Health, Inc. operates as a healthcare solutions company, providing a range of products and services to healthcare providers and patients.

What are the key factors to evaluate for ACH?

Accendra Health, Inc. (ACH) holds a MoonshotScore in the low range. To weigh it, read the analyst view under Analyst targets & estimates on this page. Accendra Health operates in two segments: Products & Healthcare Services and Patient Direct, providing a diversified revenue stream. Not financial advice.

How frequently does ACH data refresh on this page?

ACH's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ACH's recent stock price performance?

Accendra Health, Inc. (ACH) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified product and service offerings. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ACH overvalued or undervalued right now?

Accendra Health, Inc. (ACH) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Its analyst consensus target is listed under Analyst targets & estimates on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 5, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 75 figures on this page — 2 from SEC filings and earnings calls, 64 from Financial Modeling Prep (FMP), 3 with no recorded source, 4 computed by us, formula shown in the register and 2 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.